Khapzory Approval History
Reviewed on Oct 20, 2018 by J.Stewart B.Pharm
FDA Approved: Yes (First approved October 19, 2018)
Brand name: Khapzory
Generic name: levoleucovorin
Dosage form: for Injection
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Methotrexate Rescue, Folic Acid Antagonist Overdose, Colorectal Cancer
Khapzory (levoleucovorin) is a folate analog indicated for:
- rescue after high-dose methotrexate therapy in patients with osteosarcoma
- diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination
- treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
Important Safety Information for Khapzory
- Khapzory is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid, or folinic acid.
Warnings and Precautions
- Increased gastrointestinal toxicities with fluorouracil: Gastrointestinal toxicities, including stomatitis and diarrhea, occur more commonly and may be of greater severity and of prolonged duration. Deaths from severe enterocolitis, diarrhea, and dehydration have occurred in elderly patients receiving weekly d,l-leucovorin and fluorouracil. Do not initiate or continue therapy with Khapzory and fluorouracil in patients with symptoms of gastrointestinal toxicity until those symptoms have resolved. Monitor patients with diarrhea until it has resolved as rapid deterioration leading to death can occur.
- Drug interaction with trimethoprim-sulfamethoxazole: Concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis jiroveci pneumonia in patients with HIV infection increased treatment failure and morbidity.
- The most common adverse reactions (≥20%) in patients receiving high-dose methotrexate therapy with levoleucovorin rescue were stomatitis (38%) and vomiting (38%).
- The most common adverse reactions (>50%) in patients receiving levoleucovorin in combination with fluorouracil for metastatic colorectal cancer were stomatitis (72%), diarrhea (70%), and nausea (62%).
Leucovorin products increase the toxicity of fluorouracil.
Use in Specific Populations
Levoleucovorin is administered in combination with methotrexate or fluorouracil, which can cause embryo-fetal harm. Refer to methotrexate and fluorouracil prescribing information for additional information.
Development History and FDA Approval Process for Khapzory
|Oct 23, 2018||Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.